Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Executive Summary
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
You may also be interested in...
New Medicare Payment Models Should Not Be All About Saving Money, CMMI’s Fowler Says
CMS’s Innovation director Elizabeth Fowler wants to ‘reignite’ momentum behind health care system transformation. What does that mean for biopharma?
Becerra Takes The Helm At HHS; More Visibility On Administration’s Drug Pricing Priorities To Follow
Becerra’s HHS has a new crop of former Capitol Hill staffers in its policy ranks who are well versed on legislation in the health care realm, including prescription drug pricing reform. That will help advance the Administration’s agenda.
CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.